Double trouble for CML

Sci Transl Med. 2017 Apr 5;9(384):e2773. doi: 10.1126/scitranslmed.aan2773.

Abstract

Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.

Publication types

  • Comment

MeSH terms

  • Fusion Proteins, bcr-abl*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Neoplasm Recurrence, Local
  • Niacinamide / analogs & derivatives
  • Protein Kinase Inhibitors
  • Pyrazoles

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • asciminib
  • Niacinamide
  • Fusion Proteins, bcr-abl